Jazz Pharmaceuticals PLC (JAZZ)
125.10
+5.86
(+4.91%)
USD |
NASDAQ |
Nov 21, 16:00
126.97
+1.87
(+1.49%)
Pre-Market: 08:39
Jazz Pharmaceuticals Revenue (Quarterly): 1.055B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.055B |
| June 30, 2024 | 1.024B |
| March 31, 2024 | 901.98M |
| December 31, 2023 | 1.012B |
| September 30, 2023 | 972.14M |
| June 30, 2023 | 957.32M |
| March 31, 2023 | 892.81M |
| December 31, 2022 | 972.12M |
| September 30, 2022 | 940.65M |
| June 30, 2022 | 932.88M |
| March 31, 2022 | 813.72M |
| December 31, 2021 | 896.73M |
| September 30, 2021 | 838.12M |
| June 30, 2021 | 751.81M |
| March 31, 2021 | 607.58M |
| December 31, 2020 | 665.52M |
| September 30, 2020 | 600.89M |
| June 30, 2020 | 562.44M |
| March 31, 2020 | 534.73M |
| December 31, 2019 | 581.74M |
| September 30, 2019 | 537.70M |
| June 30, 2019 | 534.13M |
| March 31, 2019 | 508.19M |
| December 31, 2018 | 476.46M |
| September 30, 2018 | 469.37M |
| Date | Value |
|---|---|
| June 30, 2018 | 500.48M |
| March 31, 2018 | 444.61M |
| December 31, 2017 | 436.40M |
| September 30, 2017 | 411.86M |
| June 30, 2017 | 394.39M |
| March 31, 2017 | 376.05M |
| December 31, 2016 | 396.62M |
| September 30, 2016 | 374.18M |
| June 30, 2016 | 381.16M |
| March 31, 2016 | 336.01M |
| December 31, 2015 | 340.88M |
| September 30, 2015 | 340.87M |
| June 30, 2015 | 333.75M |
| March 31, 2015 | 309.30M |
| December 31, 2014 | 328.14M |
| September 30, 2014 | 306.58M |
| June 30, 2014 | 291.23M |
| March 31, 2014 | 246.92M |
| December 31, 2013 | 235.77M |
| September 30, 2013 | 232.16M |
| June 30, 2013 | 208.25M |
| March 31, 2013 | 196.24M |
| December 31, 2012 | 183.70M |
| September 30, 2012 | 175.52M |
| June 30, 2012 | 124.23M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
534.73M
Minimum
Mar 2020
1.055B
Maximum
Sep 2024
825.70M
Average
894.77M
Median
Revenue (Quarterly) Benchmarks
| Avadel Pharmaceuticals PLC | 50.02M |
| Alkermes PLC | 378.14M |
| Medtronic PLC | 8.403B |
| Perrigo Co PLC | 1.088B |
| Iterum Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 215.06M |
| Total Expenses (Quarterly) | 794.76M |
| EPS Diluted (Quarterly) | 3.42 |
| Enterprise Value | 11.06B |
| Gross Profit Margin (Quarterly) | 89.42% |
| Profit Margin (Quarterly) | 20.38% |
| Earnings Yield | 5.68% |
| Operating Earnings Yield | 8.16% |
| Normalized Earnings Yield | 5.874 |